Common Cold Clinical Trial
Official title:
A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, Single-Dose, Pilot Study To Evaluate Efficacy Of Dextromethorphan Hydrobromide On Acute Cough In A Pediatric Population
Verified date | August 2012 |
Source | Pfizer |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
15 mg dextromethorphan hydrobromide will be better than placebo with respect to reducing the number of coughs over 6 hours and reducing the subjective severity of cough over 6 hours.
Status | Terminated |
Enrollment | 140 |
Est. completion date | March 2011 |
Est. primary completion date | March 2011 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Years to 11 Years |
Eligibility |
Inclusion Criteria: Male or female healthy children ages 6 to under 12 years who are symptomatic with a cough due to a cold or acute URTI characterized by: - Onset of cold/URTI symptoms occurring no more than 10 days prior to Visit 1; - At least 5 coughs during the second 30-minute period of the 60-minute baseline period. General good health, aside from a common cold, and has no contraindications to the study or rescue medication Exclusion Criteria: - Acute, subchronic, or chronic cough due to any other condition other than a common cold History of clinically significant cardiovascular, pulmonary, hepatic, renal, neurological, hematological, autoimmune, psychiatric, metabolic, gastro-intestinal or endocrine disease |
Country | Name | City | State |
---|---|---|---|
United States | Cyn3rgy Research | Gresham | Oregon |
United States | Concentrics Center for Research | Indianapolis | Indiana |
United States | Clinical Research Associates Incorporated | Nashville | Tennessee |
United States | DMI Research | Pinellas | Florida |
Lead Sponsor | Collaborator |
---|---|
Pfizer | AccuDial Pharmaceutical, Boehringer Ingelheim, McNeil Consumer Healthcare Division of McNEIL-PPC, Inc., Novartis, Perrigo Company, Procter and Gamble, Reckitt Benckiser LLC |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Total Cough Count | Total cough count was done by trained assessors using continuous digital video and audio recordings. | Up to 6 hours post-dose | |
Secondary | Change From Baseline in Perceived Verbal Cough Severity Scale for 6 Hour Post-Dose Period | Perceived verbal cough severity score was assessed on a 5-point categorical rating scale in accordance to the question "How much have you coughed in the last hour?", where 0 = not at all, 1 = a tiny bit, 2 = a little, 3 = some and 4 = a lot. The change from baseline over the 6-hour post-dosing period calculated as the average of change from baseline [that is (i.e.) baseline value minus the post baseline value] measurements of Hour 1 to Hour 6, thus the change from baseline ranged from -4 to 4; higher score indicated a better improvement. | Baseline, 1, 2, 3, 4, 5, 6 hours post-dose | |
Secondary | Change From Baseline in Verbal Cough Severity Scale at Hours 1, 2, 3, 4, 5 and 6 | Verbal cough severity score was assessed on a 5-point categorical rating scale in accordance to the question "How much have you coughed in the last hour?", where 0 = not at all, 1 = a tiny bit, 2 = a little, 3 = some and 4 = a lot. The change from baseline values were derived by subtracting each post baseline value from the baseline value, and ranged from -4 to 4; higher score indicated a better improvement. | Baseline, 1, 2, 3, 4, 5, 6 hours | |
Secondary | Change From Baseline in Perceived Numerical Cough Severity Scale for 6 Hour Post-Dose Period | Perceived numerical cough severity score was assessed on an 11-point categorical rating scale in accordance to the question "How much have you coughed in the last hour?", where 0 = did not cough at all and 10 = cough a lot. The change from baseline for the 6-hour post-dosing period was calculated as the average of change from baseline (i.e. baseline value minus the post baseline value) measurements of Hour 1 to Hour 6, thus the change from baseline values ranged from -10 to 10; higher score indicated a better improvement. | Baseline, 1, 2, 3, 4, 5, 6 hour post-dose | |
Secondary | Change From Baseline in Numerical Cough Severity Scale at Hours 1, 2, 3, 4, 5 and 6 | Numerical cough severity score was assessed on an 11-point categorical rating scale in accordance to the question "How much have you coughed in the last hour?", wherein 0 = did not cough at all and 10 = cough a lot. The change from baseline was derived by subtracting the post baseline value from the baseline value and ranged from -10 to 10; higher score indicated a better improvement. | Baseline, 1, 2, 3, 4, 5, 6 hours | |
Secondary | Participants' Global Assessment of Cough: Cough Severity | Participant global assessment of cough with the assistance of parent or legal guardian was scored on a 5-point categorical scale based on response to the question " How much have you coughed in the past 6 hours?" where 0 = not at all, 1 = a tiny bit, 2 = a little, 3 = some and 4 = a lot. | Within 5 minutes after Hour 6 | |
Secondary | Participants' Global Assessment of Cough: Relief From Cough | Participant global assessment of cough with the assistance of parent or legal guardian was scored on a 5-point categorical scale based on response to the question "From when you woke up this morning until now, how much better is your cough?" where 0 = not at all better, 1 = a tiny bit better, 2 = a little better, 3 = better and 4 = a lot better. | Within 5 minutes after Hour 6 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05269290 -
Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections
|
Phase 3 | |
Completed |
NCT02451163 -
DBRCT on the Effect of Wheat Polysaccharides on Common Cold Infections in Elderly
|
Phase 2 | |
Completed |
NCT01944631 -
Iota-Carrageenan Nasal Spray in Common Cold
|
Phase 4 | |
Completed |
NCT01651715 -
Efficacy and Safety Study of Homeopathic Oral Antibodies to Treat Viral Upper Respiratory Tract Infections
|
Phase 1/Phase 2 | |
Completed |
NCT00963443 -
Acetylsalicylic Acid Combined With Pseudoephedrine in Common Cold
|
Phase 3 | |
Completed |
NCT00778648 -
Encapsulated Juice Powder Concentrate for Preventing Common Cold Symptoms
|
N/A | |
Completed |
NCT00065715 -
Echinacea Versus Placebo Effect in Common Cold (Physician Echinacea Placebo)
|
Phase 3 | |
Completed |
NCT00032500 -
Evaluation of Echinacea for the Common Cold
|
Phase 2 | |
Not yet recruiting |
NCT05070650 -
Efficacy and Safety of the Combination of Acetylcysteine, Paracetamol and Phenylephrine for the Treatment of Common Cold
|
Phase 3 | |
Not yet recruiting |
NCT04073511 -
Herbal Medicine 'Eungyosan' and 'Samsoeum' for Common Cold
|
N/A | |
Completed |
NCT04144491 -
Effect of L. Rhamnosus Yoba on RTI and Other Health Outcomes Among Children (3-6 Years) in Uganda
|
N/A | |
Completed |
NCT03189537 -
Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections
|
Phase 3 | |
Terminated |
NCT01964885 -
Benefit and Tolerability of IQP-AS-105 in Reducing Susceptibility to Upper Respiratory Tract Infections
|
Phase 3 | |
Completed |
NCT01277081 -
Effect of Paracetamol on the Common Cold
|
Phase 2 | |
Completed |
NCT01728090 -
Effectiveness of a Handwashing Programme in the Prevention of School Absenteeism Due to Respiratory Infections
|
Phase 4 | |
Completed |
NCT00405509 -
The Natural History of Viral Upper Respiratory Infections in Children Aged 6 to Less Than 14 Years
|
N/A | |
Completed |
NCT01033526 -
Symptomatic Treatment of Common Cold Symptoms
|
Phase 4 | |
Completed |
NCT05556148 -
Otrivine: Quality of Life (QoL) Impact in a Real-World Setting
|
Phase 4 | |
Terminated |
NCT03339726 -
Randomized, Double-blind, Placebo-Controlled, Efficacy Study of a New Formulation of Phenylephrine HCL in the Common Cold
|
Phase 2 | |
Completed |
NCT01361399 -
Active and Placebo Controlled Study to Test the Efficacy and Safety of an Aspirin-Lidocaine Lozenge in the Symptomatic Treatment of Sore Throat Associated With a Common Cold
|
Phase 3 |